Fly Intel: Top five analyst downgrades

Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Lucira Health (LHDX) downgraded to Underperform from Buy at BofA with analyst Derik de Bruin saying the company's preliminary Q1 revenue guidance was well short of his estimate of $12.5M, and the discussions with the management suggested that the miss was due to a lack of demand for the company's prescription at home / point-of-care test for COVID-19. 2. Aphria (APHA) downgraded to Hold from Speculative Buy at Canaccord with analyst Matt Bottomley saying the company reported fiscal Q3 financial results that came in below expectations and noted sizable headwinds related to COVID-19 lockdown protocols, decreased pricing and the decision of most provincial buyers to lower their overall inventory levels. 3. Ehang (EH) downgraded to Equal Weight from Overweight at Morgan Stanley with analyst Tim Hsiao saying while EHang has an early-mover advantage, qualified products, and established global partnerships in the passenger-grade autonomous aerial vehicles market, Hsiao thinks the "tipping point of industry demand and EHang's operational breakthroughs will likely hinge on global regulatory approvals." 4. Golar LNG (GLNG) downgraded to Underperform from Buy at BofA with analyst Ken Hoexter arguing that Iain Ross' resignation as CEO, which marks Golar's sixth CEO in 10 years, highlights the difficulty in creating a new strategic direction for the company. 5. Luminex (LMNX) downgraded to Neutral from Buy at BTIG with analyst Sung Nam saying while the offer price "seems quite favorable" for DiaSorin, there is scarcity of potential acquirers that could maximize value across all of Luminex's businesses and product portfolio. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.